Factor VIII in vitro bioequivalence of denecimig (Mim8) hemostatic effect by thrombin generation assays

This publication has 39 references indexed in Scilit:

• In vitro effects of Mim8 and combined Mim8-bypassing therapy on thrombin generation, thromboelastography and fibrin clot ultrastructure
  Thrombosis Research, 2025
• Emicizumab is well tolerated and effective in people with congenital hemophilia A regardless of age, severity of disease, or inhibitor status: a scoping review
  Research and Practice in Thrombosis and Haemostasis, 2024
• FRONTIER1: a partially randomized phase 2 study assessing the safety, pharmacokinetics, and pharmacodynamics of Mim8, a factor VIIIa mimetic
  Journal of Thrombosis and Haemostasis, 2023
• A bispecific antibody NXT007 exerts a hemostatic activity in hemophilia A monkeys enough to keep a nonhemophilic state
  Journal of Thrombosis and Haemostasis, 2023
• Mim8, a novel factor VIIIa mimetic bispecific antibody, shows favorable safety and pharmacokinetics in healthy adults
  Research and Practice in Thrombosis and Haemostasis, 2023
• In vitro effects of combining Mim8 with factor VIII, FVIIa, and activated prothrombin complex concentrates in thrombin generation assays
  Journal of Thrombosis and Haemostasis, 2023
• Haemophilia
  Nature Reviews Disease Primers, 2021
• Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study
  Thrombosis and Haemostasis, 2020
• Emicizumab, a humanized bispecific antibody to coagulation factors IXa and X with a factor VIIIa-cofactor activity
  International Journal of Hematology, 2018
• Thrombin generation assays for global evaluation of the hemostatic system: perspectives and limitations
  Revista Brasileira de Ginecologia e Obstetrícia, 2017